SNN vs SYK: Which Is the Better Buy in 2026?
Last updated August 2026
Short answer
SYK is the larger of the two ($124.86B market cap): the incumbent the market prices for continued execution (19.43x forward earnings, beta 0.78). SNN is the smaller challenger ($12.25B), cheaper on forward earnings (12.06x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
SNN vs SYK: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | SNN | SYK | What it tells you |
|---|---|---|---|
| Market cap | $12.25B | $124.86B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 12.06 | 19.43 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 19.90 | 37.74 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.69 | 0.78 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 7% of range | 39% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 12.02 | 5.43 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: SNN is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how SNN and SYK affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. SNN and SYK share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined SNN and SYK exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Smith & Nephew (SNN) do?
Smith & Nephew sells implants and consumables into the operating room and the wound clinic, and it runs three global business units. Orthopaedics, the largest at $2,437 million of 2025 revenue, covers knee implants, hip implants, other reconstruction and a trauma and extremities line. Sports Medicine & ENT, $1,934 million in 2025, sells arthroscopic repair systems, the REGENETEN bioinductive implant for rotator cuff repair, visualisation and resection hardware, and ear, nose and throat instruments. Advanced Wound Management, $1,793 million, spans foam and antimicrobial dressings, negative pressure wound therapy devices such as PICO and RENASYS, and a bioactives portfolio that includes SANTYL and skin substitutes. Group revenue was $6,164 million in 2025, up 6.1% reported and 5.3% underlying, and the business employs roughly 17,000 people. Around half of sales come from the United States: US revenue was $1,591 million of the $3,097 million booked in the first half of 2026. Emerging markets, where the company grew 10.6% underlying in that half, are the fastest-moving geography and also the source of the China pricing risk described below. The customer is a hospital or a surgical centre, the sale is usually a consumable or an implant rather than a capital item, and revenue is therefore closely tied to elective procedure volumes in the United States, Europe and Japan.
What does Stryker Corporation (SYK) do?
Stryker Corporation is a global medical technology company organized into two reportable segments: MedSurg and Neurotechnology (about 62% of 2025 sales) and Orthopaedics (about 38%). Its products include surgical instruments and navigation, endoscopy and communications systems, patient handling and emergency medical equipment, minimally invasive vascular and neurovascular devices, and orthopaedic implants for hips, knees, and trauma. The company's signature differentiator is Mako robotic-arm assisted surgery, which pulls hospitals into Stryker's ecosystem of implants and enabling technology; in early 2026 Stryker recast its Orthopaedics operations into a new Ortho Tech business that pairs orthopaedic instruments with Mako and enabling technologies.
SNN vs SYK: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- SNN drivers: Sports Medicine is doing the compounding; Orthopaedics margin ahead of Orthopaedics revenue.
- SYK drivers: Mako robotics and enabling technology; MedSurg and Neurotechnology breadth.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The clearest risk is that US Orthopaedics does not turn. For SYK, stryker trades at a premium valuation, so any slowdown in organic growth or margin progress can pressure the multiple.
SNN or SYK: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick SNN if you believe its drivers more; SYK if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the SNN and SYK guides.
SNN vs SYK: the full fundamentals
SNN. The multiple sits well below the large-cap orthopaedic peer group, and the reason is visible in the segment table rather than in any accounting subtlety: the largest franchise earns the lowest margin and is not growing. Investors buying at ~14 times adjusted earnings are paying for the RISE targets to close that gap, or for someone to force the issue on portfolio structure.
SYK. Stryker trades around $330 per share with a market cap near $127 billion, a premium franchise multiple that reflects its consistent growth record. Trailing P/E has run in the high-30s while the forward P/E sits closer to 22x on expected earnings growth. The Q1 2026 cyber incident dented near-term results, but management reaffirmed full-year organic growth guidance of 8.0% to 9.5%.
Headline figures (approximate, August 2026): SNN shows revenue (ttm) ~$6.30 billion for the twelve months to June 27, 2026, derived from 2025 revenue of $6,164 million plus first-half 2026 revenue of $3,097 million less first-half 2025 revenue of $2,961 million. Full-year 2025 revenue grew 6.1% reported and 5.3% underlying, from $5,810 million in 2024 and $5,549 million in 2023. First-half 2026 growth was 4.6% reported but only 2.3% underlying, with a 230 basis point currency tailwind and one fewer trading day. Everything here is reported in US dollars, the company's actual reporting currency, so no conversion from sterling is involved., earnings and adjusted earnings Attributable profit of ~$635 million for the twelve months to June 27, 2026, giving basic EPS of ~74.2 cents per ordinary share, or roughly $1.48 per ADS at the two-for-one ratio. Full-year 2025 EPS was 72.1 cents, up 52.8%, on operating profit of $794 million. The company's preferred measure runs well above that: trading profit was $1,211 million in 2025 (19.7% margin) and ~$1,254 million on a trailing basis, with adjusted EPS of 102.0 cents per ordinary share in 2025 and ~106.8 cents trailing, about $2.14 per ADS. The gap between operating and trading profit, roughly $440 million, is restructuring, acquisition amortisation and legal items., franchise mix and margins 2025 revenue split Orthopaedics $2,437 million, Sports Medicine & ENT $1,934 million and Advanced Wound Management $1,793 million, with segment trading margins of 14.9%, 23.8% and 24.9% respectively. In the first half of 2026 that became Orthopaedics $1,213 million (down 0.1% underlying, 13.0% margin), Sports Medicine & ENT $1,017 million (up 7.7%, 24.7% margin) and Advanced Wound Management $867 million (down 0.1% underlying, 22.0% margin). Geographically, US revenue was $1,591 million of the $3,097 million half, other established markets $958 million, and emerging markets $548 million growing 10.6% underlying., cash flow and balance sheet Free cash flow of ~$823 million on a trailing basis, after $836 million in 2025 against a $625 million internal target. First-half 2026 cash from operations was $605 million, up 6.9%, while free cash flow slipped to $231 million on ~$51 million of extra capex for a new UK wound factory and IT upgrades. Net debt was $3,019 million at June 27, 2026 (including $197 million of lease liabilities), up from $2,747 million at December 31, 2025, and adjusted net debt to EBITDA was 1.8 times. In June 2026 the group issued a EUR 500 million 4.25% bond due 2038. Nothing matures in the second half of 2026; $350 million of corporate bonds and $140 million of private placement notes fall due in the first half of 2027.; SYK shows revenue (2025) ~$25.1B, q1 2026 revenue ~$6.0B (+2.6% YoY), 2026 adj. eps guidance ~$14.90-$15.10, market cap ~$127B.
The bottom line: SNN vs SYK
SNN and SYK are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined SNN and SYK exposure against your real portfolio. It is not an investment adviser.
Wondering how SNN or SYK fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Smith & Nephew with AI
Connect the broker you already use and ask Walnut's AI how SNN fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between SNN and SYK?
+
Smith & Nephew sells implants and consumables into the operating room and the wound clinic, and it runs three global business units. Stryker Corporation is a global medical technology company organized into two reportable segments: MedSurg and Neurotechnology (about 62% of 2025 sales) and Orthopaedics (about 38%). They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is SNN or SYK the better stock?
+
Neither is universally better. SYK is the larger incumbent; SNN is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, SNN or SYK?
+
On forward P/E (as of August 2026), SNN trades at 12.06x and SYK at 19.43x, so SNN is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both SNN and SYK?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of SNN vs SYK?
+
SNN: The clearest risk is that US Orthopaedics does not turn. Knee implants fell 7.2% in the US in the second quarter of 2026 and the fix depends on launches, principally LANDMARK and wider LEGION MS set deployment, that mostly land in 2027. Launches slip, surgeons switch slowly, and a competitor with four times the revenue can out-spend the response. Advanced Wound Bioactives is the second pressure point: revenue fell 8.1% underlying in the first half after the January 2026 US reimbursement reset on skin substitutes, and the full-year headwind is now expected toward the upper end of a $20 million to $40 million range. China is a third. Volume-based procurement has already compressed sports medicine pricing, the ENT tender process has been delayed into the second half of 2026, and the company has been running down channel inventory ahead of it, so the reported growth in that market is not a clean read on demand. Execution risk sits on top of all of it: hitting full-year guidance now requires second-half growth of 5.0% to 5.5% against 2.3% delivered in the first half. There is a governance gap as well. CFO John Rogers resigned on August 19, 2026 and leaves on September 30 with a search under way, and Pierre Palassian is interim. Cevian's 14.2% position could force portfolio action or leave a large overhang if the thesis is abandoned. Legacy metal-on-metal hip claims still carry provisions, adjusted net debt to EBITDA was 1.8 times at the half, and $350 million of corporate bonds plus $140 million of private placement debt fall due in the first half of 2027. SYK: Stryker trades at a premium valuation, so any slowdown in organic growth or margin progress can pressure the multiple. Q1 2026 results were hurt by a late-quarter cyber incident that compressed adjusted margins and missed EPS estimates, and full recovery depends on catching up lost sales later in the year. The company faces strong competition in robotics and implants from Zimmer Biomet, Johnson & Johnson, Medtronic, and Smith and Nephew, plus pricing pressure from hospitals and payers. Integration risk from frequent acquisitions, currency swings, and regulatory or reimbursement changes add further uncertainty. Elective-procedure volumes can also be sensitive to macro and hospital-capacity conditions.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell SNN or SYK; figures are approximate and dated (as of August 2026). Verify current data before investing.